Press Releases

GPR84 antagonist program and OXER1 antagonist program on track to meet previously stated milestones in 2023 Closed March 31, 2023 with just over CAD26.9 million cash on hand, expecting to provide...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), re-confirms that the board of directors of the Company has already established a special committee of the...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), confirms that following close of markets on April 4, 2023, the Board of Directors of the Company (the "Board")...

CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery program aiming for the development of...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter and year ended 2022 financial results after market close on

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it has received written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that a consolidation of all of the issued and outstanding common shares of the Company ("Common Shares")...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company...

Closed December 2022 with just over CAD 37 million cash on hand, expecting to provide a runway into early 2024. Plans to divest its remaining non-core assets, to further extend runway. Nominated...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it will be holding a virtual special meeting of shareholders on January 20th, 2023, to seek...

$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras development Termination of legacy CDMO agreement for cash savings of $33.1 million Net loss from continuing...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter 2022 financial results after market close on November 9,...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal...

Termination results in anticipated cash savings of $33.1 million Removes last of legacy contracts associated with former plasma-derived therapeutics business LAVAL, QC and CAMBRIDGE, ENGLAND, Aug....

$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of fezagepras. The decision to discontinue the development of...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 6,...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed in the Company's Phase 1a single ascending dose ("SAD")...

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter 2022 financial results after market close on May 10,...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal...

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M...

Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written notice (the "Notice") from the Listing Qualifications...